TVTX - Travere Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
TVTX price evolution
TVTX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $25.17 | $24.47 | $22.73 | $21.18 |
| Inventory | $6.36 | $5.98 | $4.53 | $9.41 |
| Total current assets | $324.74 | $368.98 | $481.08 | $616.77 |
| Long term investments | ||||
| Property, plant & equipment | $21.82 | $23.05 | $24.21 | $25.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $504.41 | $551.12 | $663.55 | $788.91 |
| Current liabilities | ||||
| Accounts payable | $23.2 | $25.84 | $16.73 | $41.67 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $190.04 | $121.27 | $173.23 | $177.91 |
| Long term debt | $309.96 | $378.13 | $377.69 | $377.26 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $534.86 | $535.97 | $589.48 | $588.1 |
| Shareholders' equity | ||||
| Retained earnings | -$1386.9 | -$1332.09 | -$1261.68 | -$1125.62 |
| Other shareholder equity | -$1.02 | -$1.63 | -$1.89 | -$1.46 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $21.18 | $16.65 | $16.16 | $33.1 |
| Inventory | $9.41 | $6.92 | $7.31 | $7.6 |
| Total current assets | $616.77 | $486.44 | $582.83 | $410.4 |
| Long term investments | ||||
| Property, plant & equipment | $25.54 | $30.05 | $34.3 | $35.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $788.91 | $672.59 | $776.63 | $607.4 |
| Current liabilities | ||||
| Accounts payable | $41.67 | $17.29 | $15.14 | $12.1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $177.91 | $142.16 | $124.09 | $92.7 |
| Long term debt | $377.26 | $375.55 | $226.58 | $215.3 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $588.1 | $629.73 | $474.52 | $396.2 |
| Shareholders' equity | ||||
| Retained earnings | -$1125.62 | -$1014.22 | -$765.97 | -$585.9 |
| Other shareholder equity | -$1.46 | -$2.91 | -$0.56 | -$0.9 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $62.9 | $54.12 | $41.37 | $45.06 |
| Cost of revenue | ||||
| Gross Profit | $61.27 | $52.05 | $39.87 | $40.49 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $117.3 | $119.11 | $113.64 | $123.33 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.08 | $0.09 | $0.19 | $0.07 |
| Interest expense | $0.79 | $1.63 | $3.23 | $4.33 |
| Net income | ||||
| Net income | -$54.81 | -$70.41 | -$136.06 | -$90.17 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $145.24 | $212 | $227.49 | $198.3 |
| Cost of revenue | ||||
| Gross Profit | $133.79 | $204.4 | $220.71 | $192.2 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $510.53 | $471 | $382.47 | $267.6 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.22 | $0.3 | $0.41 | |
| Interest expense | $10.43 | -$5 | -$18.15 | -$17.7 |
| Net income | ||||
| Net income | -$111.4 | -$278.5 | -$180.09 | -$169.4 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $179.63 | $133.51 | $104.9 | $55.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.3 | $0.26 | -$0.53 | $218.75 |
| Effect of exchange rate | $0.05 | -$0.4 | -$0.29 | $1.98 |
| Change in cash and equivalents | -$21.77 | -$25.88 | -$14.92 | -$3.51 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $55.78 | -$32.55 | -$137.62 | -$61.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $218.75 | $117.57 | $231.68 | $127.71 |
| Effect of exchange rate | $1.98 | -$2.79 | $1.71 | -$1.31 |
| Change in cash and equivalents | -$3.51 | -$104.06 | $80.98 | $22.33 |
News
Fundamentals
| Market cap | $1.78B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 77.91M |
| Revenue | $203.45M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$351.45M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -5.08 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.77 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.51 |
|---|---|
| ROA | -56.05% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.71 |
| Quick ratio | 1.68 |